JP2020505393A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505393A5
JP2020505393A5 JP2019540030A JP2019540030A JP2020505393A5 JP 2020505393 A5 JP2020505393 A5 JP 2020505393A5 JP 2019540030 A JP2019540030 A JP 2019540030A JP 2019540030 A JP2019540030 A JP 2019540030A JP 2020505393 A5 JP2020505393 A5 JP 2020505393A5
Authority
JP
Japan
Prior art keywords
group
alkyl
replaced
cycloalkyl
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019540030A
Other languages
English (en)
Japanese (ja)
Other versions
JP7049349B2 (ja
JP2020505393A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/051385 external-priority patent/WO2018138028A1/en
Publication of JP2020505393A publication Critical patent/JP2020505393A/ja
Publication of JP2020505393A5 publication Critical patent/JP2020505393A5/ja
Application granted granted Critical
Publication of JP7049349B2 publication Critical patent/JP7049349B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019540030A 2017-01-26 2018-01-22 ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 Active JP7049349B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17153386 2017-01-26
EP17153386.2 2017-01-26
PCT/EP2018/051385 WO2018138028A1 (en) 2017-01-26 2018-01-22 Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2020505393A JP2020505393A (ja) 2020-02-20
JP2020505393A5 true JP2020505393A5 (cg-RX-API-DMAC7.html) 2021-01-21
JP7049349B2 JP7049349B2 (ja) 2022-04-06

Family

ID=57906577

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019540030A Active JP7049349B2 (ja) 2017-01-26 2018-01-22 ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用

Country Status (5)

Country Link
US (1) US10793530B2 (cg-RX-API-DMAC7.html)
EP (1) EP3573959B1 (cg-RX-API-DMAC7.html)
JP (1) JP7049349B2 (cg-RX-API-DMAC7.html)
CN (1) CN110248929B (cg-RX-API-DMAC7.html)
WO (1) WO2018138028A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10603317B2 (en) * 2017-01-26 2020-03-31 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018138027A1 (en) * 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof
EP3573965B1 (en) * 2017-01-26 2021-06-23 Boehringer Ingelheim International GmbH Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10913720B2 (en) 2017-01-26 2021-02-09 Boehringer Ingelheim International Gmbh Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7049349B2 (ja) * 2017-01-26 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI809427B (zh) 2018-07-13 2023-07-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11808675B2 (en) * 2019-06-13 2023-11-07 Agilent Technologies, Inc. Room temperature methods for preparing biological analytes
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US628476A (en) 1898-03-18 1899-07-11 Joseph Howard Kirk Junction of cycle, motor-car, or other frames, &c.
US2505322A (en) 1945-09-14 1950-04-25 Gibson Refrigerator Co Refrigerator cabinet
US2560111A (en) 1946-11-07 1951-07-10 Raymond T Levine Buffing chuck
US2656003A (en) 1948-02-27 1953-10-20 Inst Of Inventive Res High explosive disk-shaped charge for seismic exploration
US2727340A (en) 1953-08-31 1955-12-20 Alfred S Zanotta Portable tool for reconditioning crane rails
US5356287A (en) 1987-03-16 1994-10-18 Mcintyre Kevin M Simulating presence
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7589116B2 (en) * 2003-04-03 2009-09-15 Merck & Co. Inc. Biaryl substituted pyrazoles as sodium channel blockers
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
US7834013B2 (en) * 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
CA2560111A1 (en) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2006087169A1 (en) 2005-02-15 2006-08-24 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
WO2006103503A1 (en) 2005-03-28 2006-10-05 Pfizer Japan Inc. Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
US7664629B2 (en) 2005-07-19 2010-02-16 Xerox Corporation Second language writing advisor
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JP2009530237A (ja) 2006-03-15 2009-08-27 ノイロサーチ アクティーゼルスカブ キナゾリノン及びカリウムチャネル活性化剤としてのその使用
KR20080103584A (ko) 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
RS52307B (sr) 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
RU2011102560A (ru) 2008-06-25 2012-07-27 Дайити Санкио Компани, Лимитед (Jp) Соединение карбоновой кислоты
ES2345916B1 (es) 2008-10-14 2011-09-14 Clipdorfix, S.L. Dispositivo de fijacion liberable de elementos adosados.
WO2010045258A2 (en) 2008-10-15 2010-04-22 Amgen Inc. Spirocyclic gpr40 modulators
US20110269783A1 (en) 2008-11-10 2011-11-03 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
RU2011123647A (ru) * 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, полезные в качестве ингибиторов atr киназы
EP2440541A1 (en) 2009-06-09 2012-04-18 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2799414A1 (en) 2010-05-18 2011-11-24 Merck Sharp & Dohme Corp. Spiro isoxazoline compounds as sstr5 antagonists
TWI543984B (zh) 2010-07-09 2016-08-01 艾伯維公司 作為s1p調節劑的螺-哌啶衍生物
JP5853317B2 (ja) 2010-12-01 2016-02-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インダニルオキシジヒドロベンゾフラニル酢酸
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
PE20150968A1 (es) 2012-11-28 2015-07-09 Boehringer Ingelheim Int Nuevos acidos indaniloxi dihidrobenzofuranil aceticos
WO2014086712A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
EP2963027B1 (en) 2013-02-28 2018-12-26 TiumBio Co., Ltd. Tricyclic compound and use thereof
WO2015024526A1 (en) 2013-08-23 2015-02-26 Fujian Haixi Pharmaceuticals Co., Ltd Carboxylic acid compounds in treatment of diabetes mellitus
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP7050797B2 (ja) * 2016-10-25 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用
US10913720B2 (en) 2017-01-26 2021-02-09 Boehringer Ingelheim International Gmbh Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7049349B2 (ja) * 2017-01-26 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
EP3573965B1 (en) * 2017-01-26 2021-06-23 Boehringer Ingelheim International GmbH Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10603317B2 (en) 2017-01-26 2020-03-31 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018138027A1 (en) * 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof
US10550127B1 (en) 2017-02-08 2020-02-04 Boehringer Ingelheim International Gmbh Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2020505393A5 (cg-RX-API-DMAC7.html)
JP2020505400A5 (cg-RX-API-DMAC7.html)
JP2020505402A5 (cg-RX-API-DMAC7.html)
JP2020505394A5 (cg-RX-API-DMAC7.html)
JP2020514315A5 (cg-RX-API-DMAC7.html)
JP2019535792A5 (cg-RX-API-DMAC7.html)
JP2020506205A5 (cg-RX-API-DMAC7.html)
JP2018526405A5 (cg-RX-API-DMAC7.html)
JP2018526352A5 (cg-RX-API-DMAC7.html)
JP2019532110A5 (cg-RX-API-DMAC7.html)
JP2016530259A5 (cg-RX-API-DMAC7.html)
JP2019509276A5 (cg-RX-API-DMAC7.html)
JP2015504091A5 (cg-RX-API-DMAC7.html)
JP2013544268A5 (cg-RX-API-DMAC7.html)
JP2019527203A5 (cg-RX-API-DMAC7.html)
JP2018522879A5 (cg-RX-API-DMAC7.html)
RU2016143333A (ru) Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
JP2016510323A5 (cg-RX-API-DMAC7.html)
RU2020110780A (ru) Ингибитор fgfr и его медицинское применение
JP2015511613A5 (cg-RX-API-DMAC7.html)
RU2016137832A (ru) Соединения для лечения опосредованных комплементом нарушений
JP2016534084A5 (cg-RX-API-DMAC7.html)
JP2018535963A5 (cg-RX-API-DMAC7.html)
JP2017503760A5 (cg-RX-API-DMAC7.html)
JP2012513416A5 (cg-RX-API-DMAC7.html)